Single-Arm, Prospective, Interventional Study of Helicobacter pylori Eradication Rescue Therapy with Rifabutin, Metronidazole, and Vonoprazan

被引:0
|
作者
Sue, Soichiro [1 ]
Ikeda, Ryosuke [1 ]
Ikeda, Aya [1 ]
Sato, Hiroki [1 ]
Kaneko, Hiroaki [1 ]
Irie, Kuniyasu [1 ]
Maeda, Shin [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol, Yokohama 2360004, Japan
关键词
10-day triple therapy; Helicobacter pylori; metronidazole; rifabutin; vonoprazan; 14-DAY TRIPLE THERAPY; MULTICENTER; CLARITHROMYCIN; TESTS;
D O I
10.3390/jcm13133774
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective: Rescue Helicobacter pylori eradication can be challenging. Rifabutin (RBT) demonstrates high activity against Helicobacter pylori and is incorporated into various rescue eradication regimens. This exploratory study was performed to evaluate the efficacy and safety of a rescue regimen comprising RBT, metronidazole (MNZ), and vonoprazan (VPZ). Methods: This prospective, single-center, single-arm, interventional study was performed in Japan. Eligible patients were those who underwent failed primary eradication treatment (7-day treatment with three drugs: VPZ or a proton pump inhibitor [PPI], amoxicillin [AMPC], and clarithromycin) and secondary eradication treatment (7-day treatment with three drugs: VPZ or a PPI, AMPC, and MNZ) and those who were unable to receive first- and second-line therapy because of penicillin allergy. Twenty Helicobacter pylori-positive patients were treated with RBT (150 mg twice daily), MNZ (250 mg twice daily), and VPZ (20 mg twice daily) for 10 days (RBT-MNZ-VPZ therapy). Eradication success was evaluated using the urea breath test. Drug susceptibility test results were available in 16 patients. This study is registered in the Japan Registry of Clinical Trials (jRCT031220504). Results: The intention-to-treat (ITT) and per-protocol (PP) eradication rates of RBT-MNZ-VPZ therapy were 70% (90% confidence interval [CI]: 49.2%-86.0%) and 72.2% (95% CI: 50.2%-88.4%), respectively. In the MNZ-susceptible subgroup, the ITT (n = 8) and PP (n = 7) eradication rates were 100% (90% CI: 68.8%-100%) and 100% (90% CI: 65.2%-100%). In the MNZ-resistant subgroup, the ITT (n = 8) and PP (n = 7) eradication rates were both 62.5% (90% CI: 28.9%-88.9%). All infections were RBT-susceptible. Conclusions: These findings suggest that RBT-MNZ-VPZ therapy may be a promising rescue regimen, especially in MNZ- and RBT-susceptible infections or patients with penicillin allergy.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: A single-arm, interventional study
    Sue, Soichiro
    Kondo, Masaaki
    Sato, Takeshi
    Oka, Hiroyuki
    Sanga, Katsuyuki
    Ogashiwa, Tsuyoshi
    Matsubayashi, Mao
    Kaneko, Hiroaki
    Irie, Kuniyasu
    Maeda, Shin
    JGH OPEN, 2023, 7 (01): : 55 - 60
  • [2] Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractoryHelicobacter pyloriinfection: A prospective single-arm study
    Hirata, Yoshihiro
    Yamada, Atsuo
    Niikura, Ryota
    Shichijo, Satoki
    Hayakawa, Yoku
    Koike, Kazuhiko
    HELICOBACTER, 2020, 25 (05)
  • [3] Rifabutin rescue therapy in patients with at least three Helicobacter pylori eradication failures
    Park, Yo Han
    Kim, Nayoung
    Nam, Ryoung Hee
    Seo, Ji Hyung
    Ham, Min Hee
    Kim, Sujin
    Shim, Young Kwang
    Choi, Yoon Jin
    Yoon, Hyuk
    Shin, Cheol Min
    Park, Young Soo
    Lee, Dong Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 120 - 121
  • [4] Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
    Sugimoto, Mitsushige
    Yamaoka, Yoshio
    FRONTIERS IN PHARMACOLOGY, 2019, 9
  • [5] Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy
    Sue, Soichiro
    Sasaki, Tomohiko
    Kaneko, Hiroaki
    Irie, Kuniyasu
    Kondo, Masaaki
    Maeda, Shin
    JGH OPEN, 2021, 5 (02): : 307 - 311
  • [6] 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures
    Gisbert, JP
    Calvet, X
    Bujanda, L
    Marcos, S
    Gisbert, JL
    Pajares, JM
    HELICOBACTER, 2003, 8 (02) : 90 - 94
  • [7] Rescue therapy after Helicobacter pylori eradication failure
    Gisbert, Javier P.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2011, 34 (02): : 89 - 99
  • [8] Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
    Sakurai, Kouichi
    Suda, Hiroko
    Ido, Yumi
    Takeichi, Takayuki
    Okuda, Ayako
    Hasuda, Kiwamu
    Hattori, Masahiro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (04) : 668 - 675
  • [9] Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin
    Ono, Shoko
    Kato, Mototsugu
    Nakagawa, Soichi
    Mabe, Katsuhiro
    Sakamoto, Naoya
    HELICOBACTER, 2017, 22 (03)
  • [10] The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance
    Ashida, Kiyoshi
    Honda, Youichirou
    Sanada, Katsuyuki
    Takemura, Yukiko
    Sakamoto, Shigeru
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (12) : 1255 - 1261